RMC No. 47-2022 publishes FDA-endorsed updates adding certain COVID-19 treatment medicines to the CREATE Act VAT-exempt medicines list.
Businesses selling, purchasing, prescribing, distributing, or accounting for COVID-19 treatment medicines must check whether the medicine is covered by the FDA-endorsed updates to the list of VAT-exempt medicines under the CREATE Act, because covered medicines should be treated as VAT-exempt rather than subject to 12% VAT. For pharmacies, hospitals, clinics, distributors, importers, corporate buyers, and accounting teams, the immediate compliance issue is correct VAT treatment: invoices, receipts, billing systems, purchase records, and VAT returns must reflect the exemption only for medicines included in the updated list endorsed by the Food and Drug Administration.
What RMC No. 47-2022 Changed
RMC No. 47-2022 publishes the full text of the March 29, 2022 letter from the Food and Drug Administration of the Department of Health endorsing updates to the list of VAT-exempt medicines under Republic Act No. 11534, also known as the Corporate Recovery and Tax Incentives for Enterprises Act or CREATE Act.
The key change is not a new VAT rate, but an update to the official list of medicines that may be treated as VAT-exempt. The circular states that the FDA letter endorsed the inclusion of certain medicines for COVID-19 treatment in the list of VAT-exempt medicines under R.A. No. 11534. For businesses, this matters because VAT exemption depends on whether the medicine is properly covered by the endorsed list. If the medicine is covered, the sale should not be imposed with output VAT. If it is not covered, ordinary VAT rules may continue to apply, depending on the taxpayer and the transaction.
The official citation is Revenue Memorandum Circular No. 47-2022, dated 05 April 2022. The circular was issued by the Bureau of Internal Revenue for the information and guidance of all internal revenue officers, employees, and others concerned. It directs all concerned to be guided accordingly and to give the circular wide publicity.
Why VAT-Exempt Medicines Matter Under the CREATE Act
Under the CREATE Act framework, certain qualified medicines may be exempt from value-added tax. RMC No. 47-2022 is important because it identifies an FDA endorsement updating the list for COVID-19 treatment medicines. In practical terms, a VAT exemption can affect the final price charged to patients, hospitals, clinics, pharmacies, and other buyers. It can also affect how sellers report sales, how input VAT is treated, and how invoices or official receipts are prepared.
For accounting teams, the most searched issue is usually simple but critical: whether COVID-19 medicines are VAT exempt in the Philippines. RMC No. 47-2022 confirms that the FDA endorsed updates for inclusion of certain COVID-19 treatment medicines in the VAT-exempt medicines list under R.A. No. 11534. The circular itself does not impose a new 12% VAT rate or create a separate deadline for registration. Instead, it gives official notice that the FDA-endorsed update should guide BIR personnel and concerned taxpayers.
Who Is Most Affected by RMC No. 47-2022
The taxpayers most affected are pharmacies, drugstores, hospitals, clinics, pharmaceutical distributors, importers, wholesalers, corporate procurement teams, and healthcare institutions dealing with COVID-19 treatment medicines. Any VAT-registered business selling or distributing covered medicines should review whether its point-of-sale system, invoicing format, billing software, and accounting entries properly classify the relevant medicines as VAT-exempt.
Corporate buyers are also affected. If a company purchases medicines for employees, clinics, health programs, or workplace COVID-19 response measures, it should verify whether suppliers are correctly applying VAT exemption to medicines covered by the updated list. CFOs and accountants should check supplier invoices to confirm whether VAT was charged, whether the medicine appears to fall within the FDA-endorsed update, and whether the transaction is being recorded properly for VAT reporting and audit purposes.
Healthcare providers should also coordinate tax and pharmacy inventory teams. A covered COVID-19 treatment medicine may require different billing treatment from non-covered medicines or other medical supplies. The compliance risk is not limited to overcharging VAT; it also includes wrong reporting, inconsistent invoice descriptions, and unsupported VAT-exempt sales in the event of BIR examination.
Key Compliance Requirements and Effective Date
RMC No. 47-2022 is dated 05 April 2022. The FDA letter referenced in the circular is dated March 29, 2022. The circular’s purpose is to publish the FDA endorsement for the inclusion of certain medicines for COVID-19 treatment in the list of VAT-exempt medicines under the CREATE Act.
The most important compliance requirement is documentary and classification discipline. Taxpayers should not treat all medicines, all COVID-related products, or all healthcare items as VAT-exempt merely because they are connected with COVID-19. The circular refers specifically to certain medicines for COVID-19 treatment endorsed by the FDA for inclusion in the VAT-exempt medicines list. That distinction is important. Face masks, supplies, equipment, supplements, non-covered medicines, or general healthcare goods should not automatically be reclassified based only on this issuance.
Pharmacies and distributors should review SKU-level classifications. Hospitals and clinics should review charge codes and pharmacy billing codes. Importers and wholesalers should review product descriptions, FDA documentation, purchase orders, and sales invoices. Accounting teams should confirm that VAT-exempt sales are properly segregated from VATable sales in books and returns.
For BIR compliance, sellers should maintain records showing why a medicine was treated as VAT-exempt. This may include the relevant BIR issuance, FDA endorsement, inventory description, product registration information, and transaction documents. During audit, the taxpayer should be able to demonstrate that the exemption was applied only to medicines covered by the applicable list.
Penalties and Audit Risks for Non-Compliance
RMC No. 47-2022 does not state a special penalty, surcharge, interest rate, or administrative fine specific to this update. However, ordinary tax compliance consequences may arise if a taxpayer incorrectly treats a transaction as VAT-exempt, incorrectly charges VAT, issues improper invoices, or reports sales inconsistently in VAT returns and books of account.
If a seller treats a non-covered medicine as VAT-exempt, the BIR may question the understatement of output VAT. If a seller charges VAT on a covered VAT-exempt medicine, the issue may create pricing, invoicing, customer refund, and tax reporting concerns. If a buyer claims input VAT from an invoice where VAT should not have been imposed, that claim may be vulnerable during audit. These are practical risks for pharmacies, hospitals, distributors, and corporate buyers handling large volumes of medicine purchases.
The safest approach is to align tax treatment with the official VAT-exempt medicines list, not with broad assumptions about COVID-19, healthcare, or emergency procurement. The exemption must be supported by the medicine’s inclusion in the relevant FDA-endorsed and BIR-recognized update.
Practical Steps for Businesses, CFOs, and Accountants
First, identify all COVID-19 treatment medicines sold, purchased, imported, or distributed by the business. Do not group all products under a general COVID-19 category. The review should be product-specific and medicine-specific.
Second, compare the medicine list used by the business against the FDA-endorsed updates recognized through RMC No. 47-2022. If the medicine is covered, update the VAT classification in the accounting system, POS system, billing system, and inventory records.
Third, review invoices, official receipts, billing statements, and sales reports. VAT-exempt medicines should be clearly segregated from VATable items. Mixed transactions should be carefully documented so that VAT treatment is not applied too broadly.
Fourth, train accounting, billing, pharmacy, procurement, and sales teams. The people issuing invoices and recording sales must understand that the VAT exemption applies only to covered medicines, not automatically to every product used during the pandemic.
Fifth, preserve documentation. In a BIR audit, the taxpayer should be able to show why the sale was treated as VAT-exempt, when the classification was updated, and what documents support the exemption. This is especially important for businesses with high-volume pharmacy, hospital, or distribution transactions.
Common Search Questions Answered by RMC No. 47-2022
For taxpayers searching for RMC No. 47-2022 VAT-exempt medicines, CREATE Act VAT exemption medicines, COVID-19 medicines VAT exemption Philippines, FDA list VAT-exempt medicines, or BIR VAT exemption COVID treatment medicines, the core answer is this: the BIR published the FDA’s March 29, 2022 endorsement updating the list of VAT-exempt medicines under R.A. No. 11534 to include certain medicines for COVID-19 treatment.
The practical consequence is that covered medicines should be handled as VAT-exempt, while non-covered medicines and other goods should not be assumed exempt. Businesses should confirm coverage before changing billing or tax treatment.
How Ablola, Saribong & Gueco Can Help
Ablola, Saribong & Gueco assists Philippine businesses, healthcare providers, pharmacies, importers, distributors, and corporate taxpayers in reviewing BIR issuances, VAT treatment, invoicing practices, audit risks, and tax compliance systems. For RMC No. 47-2022, the key legal and accounting task is to confirm whether specific medicines are covered by the FDA-endorsed VAT-exempt list and to align documentation, invoicing, and VAT reporting accordingly.
If your business sells, purchases, imports, distributes, or reimburses COVID-19 treatment medicines, our team can help review the VAT treatment, supporting documents, and compliance risks before they become BIR audit issues. For assistance with VAT-exempt medicines, CREATE Act tax compliance, BIR assessments, or healthcare-related tax matters, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.